The Oncology Institute(US:TOI)2026-03-12 22:02Financial Data and Key Metrics Changes - The Oncology Institute achieved its first profitable quarter as a public company from an adjusted EBITDA perspective in Q4 2025, with a revenue increase of approximately 28% year-over-year, surpassing $500 million for the first time [4][5] - Total revenue for Q4 2025 was $142 million, representing a 41.6% year-over-year growth, driven by patient growth and pharmacy contributions [20] - Adjusted EBITDA was $147,000 in Q4 2025, improving from -$7.8 million in Q4 2024 [24] Business Line Data and Key Metrics Changes - The fee-for-service business grew 9% year-over-year from $136.2 million to $148.5 million, while the capitation business grew 17.2% year-over-year from $68.7 million to $80.5 million [17] - Pharmacy revenue grew 49.6% year-over-year from $179.9 million to $269.2 million, primarily due to improved prescription attachment rates [18] Market Data and Key Metrics Changes - The company expanded its capitated footprint by initiating 9 new capitated contracts during 2025, adding approximately 260,000 patient lives under management [5] - The partnership with Elevance Health in Florida ramped up, with approximately 70,000 lives under capitated arrangements by the end of 2025 [8] Company Strategy and Development Direction - The Oncology Institute aims to continue scaling its value-based care platform and expects over 80% growth in capitated revenue for 2026 [11] - The company plans to launch a proprietary new network portal in Q2 2026 to enhance engagement with providers and improve operational efficiencies [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow and manage industry-leading medical loss ratio (MLR) performance under its delegated capitation model [13] - The company views the potential lower rate environment for Medicare Advantage as a tailwind, as it allows for proactive engagement with payers seeking to improve care delivery [74] Other Important Information - The company reduced debt on its convertible preferred note by $24 million and ended the year with $33.6 million in cash [8] - The leadership team was strengthened with new appointments, including a Chief Clinical Officer and a Chief Administrative Officer [10] Q&A Session Summary Question: What drove the higher dispensing revenue in Q4? - The strong performance was driven by operational execution in mitigating leakage of prescriptions and strong patient encounter growth related to capitated contract growth [31] Question: Will the Elevance contract double in size in 2026? - Yes, that is the goal [32] Question: What is the size of the total addressable market for Elevance or Humana? - There is significant opportunity for growth, with many multiples of current capitated revenue available in the market [35] Question: Will there be a dip in profit margins due to ramping up capitated contracts? - A slight increase in MLR is expected for delegated contracts, but overall gross margins should not dip [44] Question: Can you provide details on the number of affiliated clinics? - The network has grown to over 200 providers in Florida, bringing the total to close to 300 combined [46] Question: What are the expectations for SG&A in 2026? - Improvements in SG&A as a percentage of revenue are expected, but not to the same degree as in 2025 due to growth investments [65]